Welcome to: Rimonabant Information Source (best place to buy rimonabant)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Obesity is a disease as someone who arrives on extra weight to a level so that it becomes a serious health condition and can endanger their health. Obesity is in fact the result of eating too many calories? Without doing physical activities. It is usually measured using the BMI (Body Mass Index) of your height to your body ieratio. BMI greater than 27 indicates that the person might be overweight and BMI of 30 or more an indication of his obese. Treatment of obesity, obesity treatment can be done through various ways such as diet programs, exercise and of course, the prescription of drugs such as Acomplia, Xenical.

Rimonabant Pricelist

Please wait while we load the price list
Dr. Luc Van Gaal reported at the annual congress of the European Society of Cardiology. Related Results Lancet, BMJ studies sound concern over anti-obesity drug rimonabantRimonabant improves cardiovascular risk profileRimonabant improves cardiovascular risk profileNew drug application for rimonabant pulledRimonabant enhanced weight loss success, improved lipids "I have never before seen a 27% increase in HDL [cholesterol] with any drug--not statins, not even fibrates," observed Dr. Van Gaal, professor of internal medicine and diabetology at the University of Antwerp (Belgium). At baseline, 42% of patients in the rimonabant 20-mg arm met criteria for metabolic syndrome, placing them at increased risk for cardiovascular disease. After 1 year of therapy in what will be a 2-year trial, the prevalence of metabolic syndrome was slashed by 53%.

New data on rimonabant suggest that the selective endocannabinoid type 1-receptor blocker has beneficial effects on glycemic control and other risk factors in diabetic patients. In treatment-naive patients with type 2 diabetes, 6 months of rimonabant therapy produced significantly greater improvements than did placebo in Hb[A.sub. 1c] levels, body weight, and cardiometabolic measures, according to clinical trial results presented in Cape Town, South Africa, at the International Diabetes Federation World Diabetes Congress. Related Results Lancet, BMJ studies sound concern over anti-obesity drug rimonabantRimonabant improves cardiovascular risk profileRimonabant improves cardiovascular risk profileNew drug application for rimonabant pulledRimonabant enhanced weight loss success, improved lipids In the double-blind, placebo-controlled Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients (SERENADE), 138 patients receiving rimonabant 20 mg/day were compared with 140 patients on placebo.